Vor Biopharma Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Vor is a clinical-stage cell and genome engineering company developing therapies for blood cancers. It has no approved products and has generated no product revenue.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $21.9 million | $15.3 million; up $6.6 million |
| General and administrative expense | $8.5 million | $7.5 million; up $1.0 million |
| Total operating expenses | $30.4 million | $22.8 million; up $7.6 million |
| Net loss | $28.4 million | $22.7 million |
| Net loss per share | $0.43 | $0.61; weighted-average shares increased to 66.3 million from 37.3 million |
| Net cash used in operations | $24.3 million | $22.9 million |
| Cash, cash equivalents and marketable securities | $210.2 million at March 31, 2023 | Down from $230.2 million at December 31, 2022 |
| Total assets / stockholders’ equity | $277.5 million / $230.2 million | At March 31, 2023 |
| Debt | None outstanding | Lease liabilities totaled $38.5 million |
Operating margin is not meaningful because Vor had no revenue. Cash, cash equivalents and restricted cash declined by $15.3 million during the quarter. Interest income was $2.0 million, compared with $0.1 million in Q1 2022. The company raised $3.7 million net through its at-the-market (ATM) facility and had $121.2 million of ATM capacity remaining at quarter-end.
Material changes and business developments
- R&D expense growth reflected increased clinical, manufacturing and consulting costs related to trem-cel and VCAR33 programs, higher personnel costs, and expansion-related facility costs.
- G&A expense increased mainly due to personnel, stock-based compensation and professional fees.
- Common shares outstanding increased to 66.9 million at March 31, 2023 from 66.0 million at year-end 2022, including shares sold through the ATM.
- Accumulated deficit reached $250.7 million. No material changes to significant license-agreement terms were reported.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital needs into the first quarter of 2025. This is an estimate based on assumptions; the filing says actual cash needs could be greater.
- The company expects continued significant operating losses and increased R&D spending, and will need additional capital. Future equity or convertible-debt financing could dilute shareholders; financing may not be available on acceptable terms.
- Vor expected additional trem-cel VBP101 clinical data in June 2023 and further engraftment and hematologic-protection updates by year-end 2023. It planned to submit an IND for VCAR33 ALLO in the first half of 2023. The company planned to obtain initial trem-cel and VCAR33 ALLO clinical data before submitting an IND for the combined Treatment System.
- Key risks include clinical and regulatory uncertainty, patient enrollment, manufacturing execution, reliance on third parties, intellectual-property protection and access to future funding. The filing reported no material change to previously disclosed risk factors, no material legal proceedings, and no material off-balance-sheet arrangements.
- Marketable securities had unrealized losses attributed to higher interest rates; no credit losses were recognized. Management stated that a hypothetical 100-basis-point interest-rate move would not have materially affected the financial statements.
Important facts for investors to verify
- Whether the stated clinical data and VCAR33 ALLO IND milestones were subsequently achieved, and what the data show about safety, engraftment and hematologic protection.
- Whether the projected runway into Q1 2025 remains achievable as clinical, manufacturing and facility spending evolves.
- Further cash use, financing activity and share-count changes, including use of the remaining ATM capacity.
- Progress, timing and regulatory strategy for trem-cel, VCAR33 ALLO and the proposed combination Treatment System.
- Lease commitments, future milestone or royalty obligations, and any changes in funding needs or disclosed risks.